T-ReXing Synthetic Cannabinoids─Unveiling Metabolite Features Suitable for Urine Screening by Trapped Ion Mobility HRMS
Open Access
- 27 July 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of the American Society for Mass Spectrometry
Abstract
Targeted and untargeted mass spectrometric analyses of urine, a preferred matrix for toxicological screening, require comprehensive spectral libraries of drug metabolites. To detect new synthetic cannabinoids (SCs), biomarkers for newly emerging compounds must be incorporated rapidly. Unfortunately, reference standards for metabolites of new psychoactive substances (NPS) such as SCs are scarce. Since parent SCs are rarely detectable in urine, elucidating their metabolism poses a significant challenge for forensic toxicology laboratories. Untargeted high-resolution mass spectrometry (HRMS) approaches, often complemented by in silico methods, are increasingly vital to forensic toxicology and metabolomics. A pooled human liver microsome (pHLM) assay was used for in vitro generation of phase I metabolites of three prevalent SCs (ADB-BUTINACA, MDMB-BUTINACA, and MDMB-4en-PINACA). Analysis was performed by trapped ion mobility spectrometry-time-of-flight mass spectrometry (timsTOF-MS) using parallel accumulation serial fragmentation (PASEF) acquisition and MetaboScape software with the T-ReX (time-aligned region complete extraction) 4D workflow including in silico metabolite prediction, fragmentation, and collision cross section (CCS) forecasting. In addition, hydrolyzed and nonhydrolyzed SC-positive urine samples were reanalyzed with this workflow. Results showed successful annotation of predicted metabolites for all three SCs, including monohydroxylations and ester hydrolysis. Qualitative pHLM and urine findings were in good agreement. Compound-specific and most abundant in vivo metabolites were incorporated into a targeted UHPLC-QTOF-MS method to analyze 42 urine samples from the casework. Although complex multistep biotransformation reactions (e.g., ADB-BUTINACA dihydrodiol formation) continue to pose a challenge for in silico prediction, this approach is significantly less time-consuming and less labor-intensive than manual evaluation of known metabolic patterns.Keywords
Funding Information
- Albert-Ludwigs-Universität Freiburg (NA)
This publication has 72 references indexed in Scilit:
- A Novel Workflow for Fast Elucidation of Drug Metabolites for Screening—Combining In Silico Metabolite Prediction With Trapped Ion Mobility QTOF‐MSDrug Testing and Analysis, 2026
- Acute toxicity of ADB‐CHMINACA ‐ a case series of patients with pronounced central nervous symptoms including the posterior reversible encephalopathic syndromeBritish Journal of Clinical Pharmacology, 2026
- “Do It Yourself” Synthetic Cannabinoid Receptor Agonist Precursors as a Ban‐Evading Strategy: Comparison of the Pharmacological Characteristics of Precursors and Their Final ProductsDrug Testing and Analysis, 2025
- Annual Banned‐Substance Review 17th Edition—Analytical Approaches in Human Sports Drug Testing 2023/2024Drug Testing and Analysis, 2024
- The metabolism of the synthetic cannabinoids ADB‐BUTINACA and ADB‐4en‐PINACA and their detection in forensic toxicology casework and infused papers seized in prisonsDrug Testing and Analysis, 2021
- HepG2 as promising cell‐based model for biosynthesis of long‐term metabolites: Exemplified for metandienoneDrug Testing and Analysis, 2021
- Characteristics of the designer drug and synthetic cannabinoid receptor agonist AM‐2201 regarding its chemistry and metabolismJournal of Mass Spectrometry, 2013
- The Biochemistry of Drug Metabolism – An IntroductionChemistry & Biodiversity, 2009
- The Biochemistry of Drug Metabolism – An IntroductionChemistry & Biodiversity, 2008
- SyGMa: Combining Expert Knowledge and Empirical Scoring in the Prediction of MetabolitesChemMedChem, 2008